Purple Biotech Stock Discussion

$Purple Biotech (PPBT.US)$
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Monday, 2nd December at 7:00 am
• Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints
• A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the c...

$Purple Biotech (PPBT.US)$ Reuters· 1 min ago
Purple Biotech Reports Positive Final Results From Randomized Phase 2 Study of Cm24 in Second Line Pancreatic Cancer

$Purple Biotech (PPBT.US)$ comeback 🔝🔝

$Draganfly (DPRO.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Alaunos Therapeutics (TCRT.US)$ $Purple Biotech (PPBT.US)$ $Homestolife (HTLM.US)$ $Pulmatrix (PULM.US)$ $SCWorx (WORX.US)$ $Interactive Strength (TRNR.US)$ $Infobird Software (IFBD.US)$ $Cyclerion Therapeutics (CYCN.US)$ $IM Cannabis (IMCC.US)$ $Unusual Machines (UMAC.US)$ $VCI Global (VCIG.US)$
📊⚡️📊

$D-Wave Quantum (QBTS.US)$ $Arqit Quantum (ARQQ.US)$ $Quantum Computing (QUBT.US)$ $NOVONIX (NVX.US)$ $Allot (ALLT.US)$ $Purple Biotech (PPBT.US)$ $Palladyne AI (PDYN.US)$ $KULR Technology (KULR.US)$ $Exicure (XCUR.US)$ $Quantum (QMCO.US)$ $Rigetti Computing (RGTI.US)$ $QMMM Holdings (QMMM.US)$
📊⚡️📊

$Alta Global Group (MMA.US)$ $Reviva Pharmaceuticals (RVPH.US)$ $Qualigen Therapeutics (QLGN.US)$ $NOVONIX (NVX.US)$ $Medicus Pharma (MDCX.US)$ $Hepion Pharmaceuticals (HEPA.US)$ $Purple Biotech (PPBT.US)$ $Eterna Therapeutics (ERNA.US)$ $Elong Power (ELPW.US)$ $Venus Concept (VERO.US)$ $Biofrontera (BFRI.US)$ $Exicure (XCUR.US)$
📊⚡️📊

$Purple Biotech (PPBT.US)$ Reuters· 1 min ago
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results

$Purple Biotech (PPBT.US)$ Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
 
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants
 
Lead tribody IM1240 data demonstrated...